For obsessive-compulsive disorder!

ArticleMedicine Guanlan

Do you have obsessive-compulsive disorder? According to the Chinese drug clinical trial registration and information disclosure platform, BioShin Limited (hereinafter referred to as "Biaoxin Company") has launched an international multi-center phase 3 clinical trial of troriluzole (BHV4157) for the treatment of obsessive-compulsive disorder in China

Public information shows that obsessive-compulsive disorder (Obsessive-compulsive disorder, abbreviated as OCD) is a kind of anxiety disorder, which is a neuropsychiatric disease

According to a press release issued by Standard New Zealand earlier, drug therapy is still the main treatment for obsessive-compulsive disorder

Troriluzole is a new type of glutamate regulator being developed by Standard New

According to the information from the Chinese drug clinical trial registration and information disclosure platform, troriluzole launched a randomized, open, international multi-center phase 3 clinical trial in China this time

It is worth mentioning that in addition to this phase 3 clinical trial for obsessive-compulsive disorder, Biaoxin is also carrying out two clinical studies on troriluzole in China: a randomized, double-blind, placebo-controlled phase 1 study aimed at The safety, tolerability and pharmacokinetic characteristics of troriluzole 280mg after single and multiple administrations were evaluated in Chinese healthy subjects; the other is an international multi-center phase 3 clinical trial, which aims to compare troriluzole and placebo in Long-term efficacy and safety in patients with spinocerebellar ataxia (SCA)

Reference materials:

[1] China Drug Clinical Trial Registration and Information Disclosure Platform.